Presentation of Results from the MOXIe Part 2 Study, by Dr. David Lynch

Part 2 of MOXIe was an international, multi-center, double-blind, placebo-controlled Phase 2 trial of omaveloxolone in patients with Friedreich’s ataxia.

Data Presentation: Topline Results from Year One of the CARDINAL Study of Bardoxolone Methyl in Alport Syndrome

The Phase 3 portion of CARDINAL is an international, multi-center, double-blind, placebo-controlled, randomized trial that enrolled 157 patients with chronic kidney disease caused by Alport syndrome. The primary endpoint for the study was the change in estimated glomerular filtration rate (eGFR) after 48 weeks of treatment. The key secondary endpoint for the study was the change in the off-treatment eGFR after 48 weeks of treatment and four weeks of drug withdrawal.